All the following are indicated in the long-term therapy of children with coronary abnormalities in Kawasaki disease EXCEPT:
**Core Concept**
Kawasaki disease is an acute, systemic vasculitis that predominantly affects children, leading to coronary artery aneurysms and long-term cardiovascular complications. Long-term therapy aims to prevent or reduce the risk of cardiovascular events.
**Why the Correct Answer is Right**
In the long-term management of Kawasaki disease with coronary abnormalities, aspirin and corticosteroids are often prescribed to reduce inflammation and prevent further coronary artery damage. However, the primary long-term therapy for children with coronary abnormalities in Kawasaki disease involves the use of low-dose aspirin for antiplatelet effects and corticosteroids for anti-inflammatory effects. **Option C**, low-dose warfarin, is not typically indicated as a first-line long-term therapy in children with Kawasaki disease. Warfarin is an anticoagulant used to prevent thrombosis, and its use in Kawasaki disease is generally reserved for patients with a history of thrombosis or those with significant coronary artery disease.
**Why Each Wrong Option is Incorrect**
**Option A:** Aspirin is indeed used in the long-term therapy of Kawasaki disease with coronary abnormalities, so this option is incorrect.
**Option B:** Corticosteroids, such as prednisolone, are also used in the long-term management of Kawasaki disease with coronary abnormalities, making this option incorrect.
**Option C:** Low-dose warfarin is not typically indicated as a first-line long-term therapy in children with Kawasaki disease.
**Clinical Pearl / High-Yield Fact**
Children with Kawasaki disease are at increased risk of developing cardiovascular complications, including coronary artery aneurysms and myocardial infarction. Early recognition and treatment of Kawasaki disease are crucial to prevent long-term cardiovascular damage.
**Correct Answer: C. Low-dose warfarin is not typically indicated as a first-line long-term therapy in children with Kawasaki disease.**